Evaluation and Option Agreement Sample Contracts
EVALUATION AND OPTION AGREEMENTEvaluation and Option Agreement • February 26th, 2016 • Vbi Vaccines Inc. • Biological products, (no disgnostic substances) • London
GLAXOSMITHKLINE BIOLOGICALS SA, a company registered in Belgium under number RPM Nivelles – BE – 0440 872 918 and having a place of business at 89, rue de l’Institut, B-1330 Rixensart, Belgium (herein referred to as "GSK") on the other part,
Standard Contracts
CONFIDENTIAL TREATMENT REQUESTED CONFIDENTIAL PORTIONS OF THIS DOCUMENT HAVE BEEN REDACTED AND HAVE BEEN SEPARATELY FILED WITH THE SECURITIES AND EXCHANGE COMMISSION Evaluation and Option Agreement Between Queen Mary University of London And MultiVir...Evaluation and Option Agreement • February 9th, 2015 • MultiVir Inc. • Pharmaceutical preparations
EVALUATION AND OPTION AGREEMENTEvaluation and Option Agreement • November 10th, 2021 • VYNE Therapeutics Inc. • Pharmaceutical preparations • England and Wales
This Evaluation and Option Agreement (“Option Agreement”) is entered into as of April 30, 2021 (the “Effective Date”) by and between, on the one hand, In4Derm Limited, a company incorporated and registered in Scotland with company number SC651132 with a place of business at 15 Luke Place, Broughty Ferry, Dundee, Scotland, DD5 3BN (“In4Derm”), and, on the other hand, VYNE Therapeutics Inc., a Delaware corporation with a principal place of business at 520 U.S. Highway 22, Suite 204, Bridgewater, NJ 08807 (“VYNE”). In4Derm and VYNE may be referred to herein individually as a “Party” and collectively as the “Parties”.
1 EXHIBIT 10.12 EVALUATION AND OPTION AGREEMENT AGREEMENT made as of the 30th day of December, 1996, by and between the Consumer Health Care Division of Pfizer Inc. (hereinafter referred to as "Pfizer"), a corporation organized and existing under the...Evaluation and Option Agreement • January 2nd, 1997 • Nastech Pharmaceutical Co Inc • Pharmaceutical preparations
If the foregoing accurately reflects our understanding, kindly sign and date this letter and return to the undersigned at the address above. Very truly yours, VYNE Therapeutics Inc. By: /s/ David Domzalski Name: David Domzalski Title: Chief Executive...Evaluation and Option Agreement • August 12th, 2022 • VYNE Therapeutics Inc. • Pharmaceutical preparations • England and Wales
CERTAIN IDENTIFIED INFORMATION HAS BEEN OMITTED FROM THIS DOCUMENT BECAUSE IT IS BOTH NOT MATERIAL AND WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED, AND HAS BEEN MARKED WITH “[***]” TO INDICATE WHERE OMISSIONS HAVE BEEN MADE.Evaluation and Option Agreement • May 11th, 2023 • VYNE Therapeutics Inc. • Pharmaceutical preparations
Reference is made to the Evaluation and Option Agreement (the “OLA”) dated as of April 30, 2021 by and between Tay Therapeutics (formerly known as In4Derm Limited) (“Tay”) and VYNE Therapeutics Inc. (“VYNE”), as amended by the letter agreements between Tay and VYNE dated as of June 15, 2022, July 30, 2021, November 9, 2021, and January 26, 2023. Capitalized terms used in this letter but not otherwise defined shall have the meanings ascribed to them in the OLA.
